DMI019

DMI019 is an investigational nasal spray developed by Jiangsu Demai Pharmaceutical for the treatment of allergic rhinitis. It is a chemical drug currently in Phase I clinical development in China, where it is being evaluated for safety, tolerability, and pharmacokinetics in healthy volunteers. The drug is designed for intranasal administration to provide localized relief from symptoms such as nasal congestion, rhinorrhea, and sneezing by targeting the underlying inflammatory and allergic processes in the nasal mucosa. As a product of Jiangsu Demai's pipeline, which focuses on improved formulations and complex generics, DMI019 aims to offer a localized therapeutic effect with minimal systemic exposure.